US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Liminatus Pharma LLC

0.7860

-0.0341-4.16%

Volume:104.22K

Turnover:87.28K

Market Cap:21.27M

PE:-40.25

High:0.8704

Open:0.8501

Low:0.7842

Close:0.8201

52wk High:33.66

52wk Low:0.6100

Shares:27.06M

Float Shares:4.51M

Volume Ratio:0.80

T/O Rate:2.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0195

EPS(LYR):-0.0316

ROE:--

ROA:-48.06%

PB:-12.93

PE(LYR):-24.87

Loading ...

Overview Company News Filings

Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach

Liminatus Pharma, Inc. (Nasdaq: Limn) Signs Mou With Capital Trust Group for USD 30 Million Equity Investment via an Earn-Out Mechanism and Future Strategic Cooperation

THOMSON REUTERS

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

Liminatus Pharma Receives Nasdaq Notice for Delayed Financial Report

Liminatus Pharma Inc. Files Initial Statement of Beneficial Ownership; Iris Acquisition Holdings LLC Named as Beneficial Owner

Liminatus Pharma Inc. Announces Delay in Q2 Financial Report Filing

BRIEF-Liminatus Pharma To Launch 'American BNB Strategy' Subsidiary And Target Up To $500 Mln Fund For BNB Investment As Part Of Crypto Market Initiative

Liminatus Pharma Inc. to Launch “American Bnb Strategy” Subsidiary and Target up to $500 Million Fund for Bnb Investment as Part of Crypto Market Initiative

THOMSON REUTERS

Liminatus Pharma Explores Formation of Digital Asset Investment Subsidiary

MT Newswires Live

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting up to $500 Million in Capital Strategies

THOMSON REUTERS

Liminatus Pharma Inc - Enters Agreement With Digital Offering Llc

THOMSON REUTERS

Liminatus Pharma Inc - Funding May Involve Convertible Debentures, Equity-Linked Securities

THOMSON REUTERS

Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

Liminatus Pharma Inc. Files Initial Statement of Beneficial Ownership; Philip Wayne Lemons II Named as Director

BRIEF-Liminatus Pharma Initiates Strategic Review Of Blockchain-Integrated Treasury Strategy

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Liminatus Pharma Inc. Files Initial Beneficial Ownership Statement; Richard Baek Named as Director

BRIEF-Liminatus Pharma Inc - Enters Settlement Agreement With Alta Partners - SEC Filing

Liminatus Pharma Inc. Issues 350,000 Shares in Exchange for Cancellation of 1,000,000 Warrants with Alta Partners

Liminatus Pharma Inc. Expands Board, Appoints Philip Lemons and Richard Baek as New Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LIMN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LIMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIMN\",,,,,undefined,":{"symbol":"LIMN","market":"US","secType":"STK","nameCN":"Liminatus Pharma LLC","latestPrice":0.786,"timestamp":1767982300029,"preClose":0.8201,"halted":0,"volume":104216,"delay":0,"floatShares":4505200,"shares":27064633,"eps":-0.01953,"marketStatus":"Trading","change":-0.0341,"latestTime":"01-09 13:11:44 EST","open":0.8501,"high":0.8704,"low":0.7842,"amount":87280.77910944,"amplitude":0.105109,"askPrice":0.7878,"askSize":300,"bidPrice":0.78,"bidSize":3848,"shortable":0,"etf":0,"ttmEps":-0.01953,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1767992400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8201,"preHourTrading":{"tag":"盘前","latestPrice":0.8762,"preClose":0.8201,"latestTime":"09:24 EST","volume":6770,"amount":6246.9868319,"timestamp":1767968695722},"postHourTrading":{"tag":"盘后","latestPrice":0.8161,"preClose":0.8201,"latestTime":"19:37 EST","volume":11454,"amount":9040.2576,"timestamp":1767919042509},"volumeRatio":0.797063},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIMN\",,,,,undefined,":{"symbol":"LIMN","floatShares":4505200,"roa":"-48.06%","roe":"--","lyrEps":-0.031598,"volumeRatio":0.797063,"shares":27064633,"dividePrice":0,"high":0.8704,"amplitude":0.105109,"preClose":0.8201,"low":0.7842,"week52Low":0.61,"pbRate":"-12.93","week52High":33.66,"institutionHeld":0,"latestPrice":0.786,"committee":0.855352,"eps":-0.01953,"divideRate":0,"volume":104216,"delay":0,"ttmEps":-0.01953,"open":0.8501,"prevYearClose":0.61,"prevWeekClose":0.6407,"prevMonthClose":0.61,"prevQuarterClose":0.61,"fiveDayClose":0.6407,"twentyDayClose":0.8928,"sixtyDayClose":1.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LIMN\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"LIMN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763110800000,"name":null,"time":"Pre-Market","dateTimestamp":1763096400000,"actualEps":null},{"market":"US","date":"2025-10-06","symbol":"LIMN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1759723200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-09-06","symbol":"LIMN","reason":null,"defaultRemindTime":1725629400000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1725595200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LIMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LIMN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LIMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LIMN","date":"2026-01-08","current":-41.991807,"percent":0.908642,"low":-195.659531,"twenty":-34.480682,"median":-18.780967,"eighty":-16.189831,"high":-7.282393,"avg":-28.518201,"sd":26.64354,"marketCap":25429929},"quantilePoints":[{"date":"2024-05-31","current":-29.356886,"twenty":-27.648492,"median":-26.153647,"eighty":-25.797732,"marketCap":85956962},{"date":"2024-06-07","current":-28.227775,"twenty":-27.609218,"median":-27.049572,"eighty":-26.224831,"marketCap":82650925},{"date":"2024-06-14","current":-27.12321,"twenty":-28.473234,"median":-27.160029,"eighty":-26.818841,"marketCap":79416758},{"date":"2024-06-21","current":-28.424142,"twenty":-28.841422,"median":-27.258212,"eighty":-27.034844,"marketCap":83225888},{"date":"2024-06-28","current":-28.645055,"twenty":-28.762875,"median":-28.227775,"eighty":-27.05939,"marketCap":83872721},{"date":"2024-07-05","current":-28.0805,"twenty":-28.645055,"median":-28.227775,"eighty":-27.083936,"marketCap":82219703},{"date":"2024-07-12","current":-27.442306,"twenty":-28.645055,"median":-28.092773,"eighty":-27.12321,"marketCap":80351073},{"date":"2024-07-19","current":-28.49778,"twenty":-28.645055,"median":-28.227775,"eighty":-27.137937,"marketCap":83441499},{"date":"2024-07-26","current":-27.098664,"twenty":-28.645055,"median":-28.092773,"eighty":-27.103573,"marketCap":79344888},{"date":"2024-08-02","current":-27.074118,"twenty":-28.6156,"median":-28.0805,"eighty":-27.074118,"marketCap":79273018},{"date":"2024-08-09","current":-16.785464,"twenty":-28.49778,"median":-27.761403,"eighty":-27.074118,"marketCap":79344888},{"date":"2024-08-16","current":-16.869239,"twenty":-28.49778,"median":-27.368669,"eighty":-27.074118,"marketCap":79740894},{"date":"2024-08-23","current":-15.964436,"twenty":-28.49778,"median":-27.160029,"eighty":-25.940098,"marketCap":75463888},{"date":"2024-08-30","current":-16.359746,"twenty":-28.49778,"median":-27.098664,"eighty":-16.869239,"marketCap":77332518},{"date":"2024-09-06","current":-16.800668,"twenty":-28.49778,"median":-27.098664,"eighty":-16.800668,"marketCap":79416758},{"date":"2024-09-13","current":-15.872679,"twenty":-28.424142,"median":-27.074118,"eighty":-16.724647,"marketCap":75030154},{"date":"2024-09-20","current":-16.325753,"twenty":-28.424142,"median":-27.074118,"eighty":-16.597597,"marketCap":77171833},{"date":"2024-09-27","current":-16.189831,"twenty":-28.227775,"median":-27.074118,"eighty":-16.526992,"marketCap":76529329},{"date":"2024-10-04","current":-16.688212,"twenty":-28.227775,"median":-27.074118,"eighty":-16.344693,"marketCap":78885176},{"date":"2024-10-11","current":-16.688212,"twenty":-28.227775,"median":-26.767294,"eighty":-16.359746,"marketCap":78885176},{"date":"2024-10-18","current":-16.824134,"twenty":-28.105045,"median":-25.797732,"eighty":-16.496584,"marketCap":79527680},{"date":"2024-10-25","current":-16.899646,"twenty":-28.0805,"median":-16.899646,"eighty":-16.526992,"marketCap":79884626},{"date":"2024-11-01","current":-16.899646,"twenty":-28.0805,"median":-16.899646,"eighty":-16.587809,"marketCap":79884626},{"date":"2024-11-08","current":-16.763724,"twenty":-28.0805,"median":-16.899646,"eighty":-16.587809,"marketCap":79242123},{"date":"2024-11-15","current":-16.522085,"twenty":-28.0805,"median":-16.869239,"eighty":-16.522085,"marketCap":78099894},{"date":"2024-11-22","current":-16.572225,"twenty":-28.0805,"median":-16.837108,"eighty":-16.522085,"marketCap":78336906},{"date":"2024-11-29","current":-16.572225,"twenty":-27.569945,"median":-16.824134,"eighty":-16.522085,"marketCap":78336906},{"date":"2024-12-06","current":-16.748621,"twenty":-27.442306,"median":-16.824134,"eighty":-16.522085,"marketCap":79170733},{"date":"2024-12-13","current":-17.05067,"twenty":-27.383396,"median":-16.824134,"eighty":-16.526011,"marketCap":80598519},{"date":"2024-12-20","current":-17.201695,"twenty":-27.329395,"median":-16.850082,"eighty":-16.563178,"marketCap":81312412},{"date":"2024-12-27","current":-17.201695,"twenty":-27.245939,"median":-16.869239,"eighty":-16.572225,"marketCap":81312412},{"date":"2025-01-03","current":-16.944953,"twenty":-27.167392,"median":-16.899646,"eighty":-16.572225,"marketCap":80098794},{"date":"2025-01-10","current":-16.944953,"twenty":-27.12321,"median":-16.899646,"eighty":-16.572225,"marketCap":80098794},{"date":"2025-01-17","current":-17.503744,"twenty":-27.118301,"median":-16.899646,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-01-24","current":-17.503744,"twenty":-27.098664,"median":-16.9223,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-01-31","current":-17.503744,"twenty":-27.098664,"median":-16.944953,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-02-07","current":-20.239774,"twenty":-27.098664,"median":-16.944953,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-02-14","current":-20.239774,"twenty":-27.074118,"median":-16.944953,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-02-21","current":-20.239774,"twenty":-27.074118,"median":-16.975158,"eighty":-16.572225,"marketCap":82740198},{"date":"2025-02-28","current":-20.414406,"twenty":-27.074118,"median":-17.05067,"eighty":-16.572225,"marketCap":83454091},{"date":"2025-03-07","current":-26.194704,"twenty":-27.074118,"median":-17.05067,"eighty":-16.584692,"marketCap":107083950},{"date":"2025-03-14","current":-26.194704,"twenty":-27.074118,"median":-17.201695,"eighty":-16.587809,"marketCap":107083950},{"date":"2025-03-21","current":-26.194704,"twenty":-27.074118,"median":-17.201695,"eighty":-16.595639,"marketCap":107083950},{"date":"2025-03-28","current":-15.716822,"twenty":-27.074118,"median":-17.201695,"eighty":-16.587809,"marketCap":64250370},{"date":"2025-04-04","current":-15.716822,"twenty":-27.074118,"median":-17.201695,"eighty":-16.572225,"marketCap":64250370},{"date":"2025-04-11","current":-15.716822,"twenty":-27.074118,"median":-17.05067,"eighty":-16.572225,"marketCap":64250370},{"date":"2025-04-17","current":-12.11383,"twenty":-27.074118,"median":-17.05067,"eighty":-16.554132,"marketCap":49521339},{"date":"2025-04-25","current":-9.258427,"twenty":-27.05939,"median":-16.998323,"eighty":-16.522085,"marketCap":37848451},{"date":"2025-05-02","current":-51.163808,"twenty":-27.074118,"median":-17.05067,"eighty":-16.522085,"marketCap":209157649},{"date":"2025-05-09","current":-54.655673,"twenty":-27.074118,"median":-17.05067,"eighty":-16.522085,"marketCap":193809015},{"date":"2025-05-16","current":-47.319341,"twenty":-27.098664,"median":-17.201695,"eighty":-16.522085,"marketCap":167794382},{"date":"2025-05-23","current":-40.349825,"twenty":-27.152665,"median":-17.201695,"eighty":-16.525029,"marketCap":143080481},{"date":"2025-05-30","current":-38.295653,"twenty":-27.412851,"median":-17.201695,"eighty":-16.545085,"marketCap":135796384},{"date":"2025-06-06","current":-180.473765,"twenty":-28.0805,"median":-17.201695,"eighty":-16.572225,"marketCap":639959971},{"date":"2025-06-13","current":-149.000565,"twenty":-28.178683,"median":-17.503744,"eighty":-16.572225,"marketCap":528357196},{"date":"2025-06-20","current":-93.904837,"twenty":-28.384869,"median":-17.503744,"eighty":-16.572225,"marketCap":332987302},{"date":"2025-06-27","current":-121.782835,"twenty":-28.49778,"median":-17.503744,"eighty":-16.572225,"marketCap":431842907},{"date":"2025-07-03","current":-66.173564,"twenty":-28.645055,"median":-17.503744,"eighty":-16.572225,"marketCap":234651989},{"date":"2025-07-11","current":-52.821471,"twenty":-28.645055,"median":-17.503744,"eighty":-16.572225,"marketCap":187305357},{"date":"2025-07-18","current":-40.129645,"twenty":-29.356886,"median":-17.503744,"eighty":-16.572225,"marketCap":142300042},{"date":"2025-07-25","current":-62.138591,"twenty":-38.295566,"median":-17.503744,"eighty":-16.572225,"marketCap":220343941},{"date":"2025-08-01","current":-45.998697,"twenty":-39.616103,"median":-17.637767,"eighty":-16.572225,"marketCap":163111748},{"date":"2025-08-08","current":-35.434403,"twenty":-39.616103,"median":-19.593638,"eighty":-16.572225,"marketCap":125650677},{"date":"2025-08-15","current":-30.225619,"twenty":-39.542829,"median":-20.239774,"eighty":-16.587809,"marketCap":107180287},{"date":"2025-08-22","current":-20.394957,"twenty":-38.882559,"median":-20.239774,"eighty":-16.587809,"marketCap":72320679},{"date":"2025-08-29","current":-20.24823,"twenty":-38.295653,"median":-20.239774,"eighty":-16.597597,"marketCap":71800387},{"date":"2025-09-05","current":-20.761772,"twenty":-38.295583,"median":-20.239774,"eighty":-16.597597,"marketCap":73621411},{"date":"2025-09-12","current":-15.259536,"twenty":-37.532589,"median":-20.239774,"eighty":-16.595639,"marketCap":54110436},{"date":"2025-09-19","current":-9.463847,"twenty":-37.224531,"median":-20.239774,"eighty":-16.572225,"marketCap":33558876},{"date":"2025-09-26","current":-10.637657,"twenty":-36.432159,"median":-20.239774,"eighty":-16.572225,"marketCap":37721217},{"date":"2025-10-03","current":-14.379178,"twenty":-35.595802,"median":-19.5908,"eighty":-16.563178,"marketCap":50988680},{"date":"2025-10-10","current":-39.623683,"twenty":-38.295583,"median":-20.239774,"eighty":-16.572225,"marketCap":41408888},{"date":"2025-10-17","current":-31.854333,"twenty":-37.532589,"median":-20.239774,"eighty":-16.572225,"marketCap":33289498},{"date":"2025-10-24","current":-31.077398,"twenty":-37.224531,"median":-20.239774,"eighty":-16.572225,"marketCap":32477559},{"date":"2025-10-31","current":-36.515943,"twenty":-36.858977,"median":-20.239774,"eighty":-16.572225,"marketCap":38161132},{"date":"2025-11-07","current":-33.149225,"twenty":-36.774921,"median":-20.24823,"eighty":-16.572225,"marketCap":34642730},{"date":"2025-11-14","current":-27.71068,"twenty":-36.567739,"median":-20.414406,"eighty":-16.572225,"marketCap":28959157},{"date":"2025-11-21","current":-12.535267,"twenty":-36.515943,"median":-20.414406,"eighty":-16.572225,"marketCap":28417864},{"date":"2025-11-28","current":-12.415884,"twenty":-36.515943,"median":-20.24823,"eighty":-16.572225,"marketCap":28147218},{"date":"2025-12-05","current":-11.377247,"twenty":-36.351216,"median":-20.239774,"eighty":-16.522085,"marketCap":25792595},{"date":"2025-12-12","current":-10.290857,"twenty":-36.095351,"median":-20.239774,"eighty":-16.522085,"marketCap":23329713},{"date":"2025-12-19","current":-9.668869,"twenty":-35.659836,"median":-20.239774,"eighty":-16.344693,"marketCap":21919646},{"date":"2025-12-26","current":-8.452352,"twenty":-35.245471,"median":-20.239774,"eighty":-16.2442,"marketCap":19161760},{"date":"2026-01-02","current":-7.282393,"twenty":-34.865795,"median":-19.737527,"eighty":-16.189831,"marketCap":16509426},{"date":"2026-01-08","current":-11.217273,"twenty":-34.480682,"median":-18.780967,"eighty":-16.189831,"marketCap":25429929}],"updateTime":1767951371622},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LIMN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586785404","title":"Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach","url":"https://stock-news.laohu8.com/highlight/detail?id=2586785404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586785404?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:27","pubTimestamp":1764109648,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has received notices from the Nasdaq Listing Qualifications Department indicating non-compliance with several Nasdaq listing rules. The company failed to maintain a minimum Market Value of Listed Securities of $50 million and a minimum Market Value of Publicly Held Shares of $15 million over the past 30 consecutive business days. Additionally, Liminatus does not meet requirements for total assets and revenue under another Nasdaq rule. Although these notifications do not immediately affect the company's stock listing, Liminatus is at risk of delisting if it cannot regain compliance within the prescribed timeframe. The company is actively working to address these deficiencies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL7LLTmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2579312388","title":"Liminatus Pharma, Inc. (Nasdaq: Limn) Signs Mou With Capital Trust Group for USD 30 Million Equity Investment via an Earn-Out Mechanism and Future Strategic Cooperation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579312388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579312388?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:04","pubTimestamp":1761833069,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUA4CJZHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2579123531","title":"Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579123531","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579123531?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:04","pubTimestamp":1761833040,"startTime":"0","endTime":"0","summary":"LA PALMA, Calif., Oct.  30, 2025  (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177589/0/en/Liminatus-Pharma-Inc-NASDAQ-LIMN-Signs-MOU-with-Capital-Trust-Group-for-USD-30-Million-Equity-Investment-via-an-earn-out-mechanism-and-Future-Strategic-Cooperation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MNQmain","PSQ","EQR","USJW.SI","BK4215","BK4139","NVIW.SI","SQQQ",".IXIC","NQmain","USD","BK4588","QID","LIMN","TSYW.SI","USAW.SI","QLD","TQQQ"],"gpt_icon":1},{"id":"2562127844","title":"Liminatus Pharma Receives Nasdaq Notice for Delayed Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2562127844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562127844?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:16","pubTimestamp":1756156573,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. , a pre-clinical stage biopharmaceutical company, announced on August 25, 2025, that it received a Nasdaq notification on August 22, 2025, for non-compliance with Listing Rule 5250 due to a delay in filing its Quarterly Report on Form 10-Q for the period ending June 30, 2025. The company's stock remains listed on Nasdaq, and it has until October 21, 2025, to submit a compliance plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 25, 2025, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL4lGcDr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2559894372","title":"Liminatus Pharma Inc. Files Initial Statement of Beneficial Ownership; Iris Acquisition Holdings LLC Named as Beneficial Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2559894372","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559894372?lang=en_us&edition=fundamental","pubTime":"2025-08-16 02:50","pubTimestamp":1755283851,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. Files Initial Statement of Beneficial Ownership; Iris Acquisition Holdings LLC Named as Beneficial Owner. Liminatus Pharma Inc. has filed an initial statement of beneficial ownership, identifying Iris Acquisition Holdings LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL6GfJKs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2559916804","title":"Liminatus Pharma Inc. Announces Delay in Q2 Financial Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2559916804","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559916804?lang=en_us&edition=fundamental","pubTime":"2025-08-15 18:34","pubTimestamp":1755254075,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has announced a delay in filing its financial report for the period ended June 30, 2025. The company filed a Notification of Late Filing  with the U.S. Securities and Exchange Commission, indicating that its Form 10-Q could not be submitted within the prescribed time frame. The delay was attributed to reasons that could not be resolved without unreasonable effort or expense.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for the information contained there","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL8WMRp7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2554776528","title":"BRIEF-Liminatus Pharma To Launch 'American BNB Strategy' Subsidiary And Target Up To $500 Mln Fund For BNB Investment As Part Of Crypto Market Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2554776528","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554776528?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:32","pubTimestamp":1753702340,"startTime":"0","endTime":"0","summary":"BRIEF-Liminatus Pharma To Launch 'American BNB Strategy' Subsidiary And Target Up To $500 Mln Fund For BNB Investment As Part Of Crypto Market InitiativeJuly 28 (Reuters) - Liminatus Pharma Inc LIMN.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP0TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2554370776","title":"Liminatus Pharma Inc. to Launch “American Bnb Strategy” Subsidiary and Target up to $500 Million Fund for Bnb Investment as Part of Crypto Market Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2554370776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554370776?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:30","pubTimestamp":1753702255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP0TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2554608537","title":"Liminatus Pharma Explores Formation of Digital Asset Investment Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2554608537","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554608537?lang=en_us&edition=fundamental","pubTime":"2025-07-25 20:50","pubTimestamp":1753447859,"startTime":"0","endTime":"0","summary":"Liminatus Pharma  said Friday it is exploring the formation of a $500 million digital asset investment subsidiary.The proposed subsidiary, if approved, would operate separately from Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures, the company said.Liminatus said potential capital formation could involve private placements, convertible instruments, equity line, and other structured financing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2554776718","title":"Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting up to $500 Million in Capital Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2554776718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554776718?lang=en_us&edition=fundamental","pubTime":"2025-07-25 20:32","pubTimestamp":1753446722,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nFWN3TM11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2553978854","title":"Liminatus Pharma Inc - Enters Agreement With Digital Offering Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2553978854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553978854?lang=en_us&edition=fundamental","pubTime":"2025-07-24 20:31","pubTimestamp":1753360275,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nFWN3TL1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2553885717","title":"Liminatus Pharma Inc - Funding May Involve Convertible Debentures, Equity-Linked Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2553885717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553885717?lang=en_us&edition=fundamental","pubTime":"2025-07-24 20:31","pubTimestamp":1753360275,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nFWN3TL1CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2553788094","title":"Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2553788094","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553788094?lang=en_us&edition=fundamental","pubTime":"2025-07-24 20:31","pubTimestamp":1753360260,"startTime":"0","endTime":"0","summary":"Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing pathsLA PALMA, Calif., July  24, 2025  (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/24/3121080/0/en/Liminatus-Pharma-Inc-Takes-Next-Step-in-Evaluating-Digital-Asset-Linked-Capital-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4596","STRK","BK4595","BK4600","LIMN","BK4516","BK4139","BK4023"],"gpt_icon":1},{"id":"2553476242","title":"Liminatus Pharma Inc. Files Initial Statement of Beneficial Ownership; Philip Wayne Lemons II Named as Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2553476242","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553476242?lang=en_us&edition=fundamental","pubTime":"2025-07-24 02:20","pubTimestamp":1753294829,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has filed an initial statement of beneficial ownership. The filing mentions Philip Wayne Lemons II as the beneficial owner, who serves as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL69BkJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2553570250","title":"BRIEF-Liminatus Pharma Initiates Strategic Review Of Blockchain-Integrated Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2553570250","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553570250?lang=en_us&edition=fundamental","pubTime":"2025-07-23 01:37","pubTimestamp":1753205828,"startTime":"0","endTime":"0","summary":"BRIEF-Liminatus Pharma Initiates Strategic Review Of Blockchain-Integrated Treasury StrategyJuly 22 (Reuters) - Liminatus Pharma Inc LIMN.O:LIMINATUS PHARMA, INC. INITIATES STRATEGIC REVIEW OF BLOCKCH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nTUA9VMRVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2553250604","title":"Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2553250604","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553250604?lang=en_us&edition=fundamental","pubTime":"2025-07-23 01:30","pubTimestamp":1753205400,"startTime":"0","endTime":"0","summary":"Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July  22, 2025  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/22/3119752/0/en/Liminatus-Pharma-Inc-Initiates-Strategic-Review-of-Blockchain-Integrated-Treasury-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4516","BK4595","BK4588","BK4023","LIMN","STRK","BK4585","BK4139","BK4600"],"gpt_icon":1},{"id":"2553401327","title":"Liminatus Pharma Inc. Files Initial Beneficial Ownership Statement; Richard Baek Named as Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2553401327","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553401327?lang=en_us&edition=fundamental","pubTime":"2025-07-22 04:30","pubTimestamp":1753129857,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has filed an initial statement of beneficial ownership, identifying Richard JaiHwan Baek as a beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDLc4L8ty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIMN"],"gpt_icon":0},{"id":"2552432567","title":"BRIEF-Liminatus Pharma Inc - Enters Settlement Agreement With Alta Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2552432567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552432567?lang=en_us&edition=fundamental","pubTime":"2025-07-18 06:20","pubTimestamp":1752790817,"startTime":"0","endTime":"0","summary":"BRIEF-Liminatus Pharma Inc - Enters Settlement Agreement With Alta Partners - SEC FilingJuly 17  - Liminatus Pharma Inc LIMN.O:LIMINATUS PHARMA INC - ENTERS SETTLEMENT AGREEMENT WITH ALTA PARTNERS - SEC FILINGLIMINATUS PHARMA INC - TO ISSUE 350,000 SHARES OF COMMON STOCK - SEC FILINGSource text: [ID:n0001104659-25-068670]Further company coverage: LIMN.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nFWN3TE0R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2552431130","title":"Liminatus Pharma Inc. Issues 350,000 Shares in Exchange for Cancellation of 1,000,000 Warrants with Alta Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2552431130","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552431130?lang=en_us&edition=fundamental","pubTime":"2025-07-18 04:19","pubTimestamp":1752783597,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has entered into a settlement and release agreement with Alta Partners, LLC, resulting in the issuance of 350,000 shares of its common stock to Alta Partners in exchange for the cancellation of 1,000,000 warrants to purchase shares of common stock. The shares have a par value of $0.0001 each. No commission or remuneration was involved in this transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL6R5Rbz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0},{"id":"2550961751","title":"Liminatus Pharma Inc. Expands Board, Appoints Philip Lemons and Richard Baek as New Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2550961751","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550961751?lang=en_us&edition=fundamental","pubTime":"2025-07-12 05:02","pubTimestamp":1752267772,"startTime":"0","endTime":"0","summary":"Liminatus Pharma Inc. has expanded its board of directors to six members with the appointment of Philip Lemons and Richard Baek. Philip Lemons, 54, brings over two decades of experience in clinical research and development, having held leadership roles at various global research institutions and consulting firms. Richard Baek, 33, brings expertise in financial oversight and regulatory compliance, with a background in finance roles across multiple sectors. Both appointments are effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL3x5rbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}